Aamund regrets overly-ambitious strategy in Neurosearch
![](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article3000354.ece/ALTERNATES/schema-16_9/asgeraamund_st.jpg)
From the outset, Neurosearch reached for the stars. The aim was drugs for widespread diseases such as cancer, depression and Alzheimer’s, but that strategy should have included another branch – niche medicine, admits Asger Aamund, who is co-founder and former chairman of the board in Neurosearch.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.